Literature DB >> 13981251

A trial of therapy by nucleosides and nucleotides in muscular dystrophy.

W H THOMSON, K E GUEST.   

Abstract

Entities:  

Keywords:  ADENINE NUCLEOTIDES; ADENOSINE TRIPHOSPHATE; GUANINE NUCLEOTIDES; MUSCULAR DYSTROPHY; NUCLEOSIDES; URACIL NUCLEOTIDES

Mesh：

Substances：

Year:  1963        PMID： 13981251      PMCID： PMC495546          DOI： 10.1136/jnnp.26.2.111

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  31 in total

1.  Bracing for ambulation in childhood progressive muscular dystrophy.

Authors:  G E SPENCER; P J VIGNOS
Journal:  J Bone Joint Surg Am       Date:  1962-03       Impact factor: 5.284

2.  Sources of error in the biochemical diagnosis of muscular dystrophy.

Authors:  W A THOMSON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1962-08       Impact factor: 10.154

3.  Abnormal hepatic tests in muscular disease.

Authors:  R M MORRELL
Journal:  AMA Arch Intern Med       Date:  1959-07

4.  An investigation of the carrier state in the Duchenne type muscular dystrophy.

Authors:  P LEYBURN; W H THOMSON; J N WALTON
Journal:  Ann Hum Genet       Date:  1961-05       Impact factor: 1.670

5.  Clinical trial of high dosage vitamin E in human muscular dystrophy.

Authors:  G M BERNESKE; A R BUTSON; E N GAULD; D LEVY
Journal:  Can Med Assoc J       Date:  1960-02-20       Impact factor: 8.262

6.  [The treatment of progressive muscular dystrophy (Erb) with adenosine triphosphate].

Authors:  P STELGENS
Journal:  Dtsch Med Wochenschr       Date:  1957-10-11       Impact factor: 0.628

7.  Contributions to the study of nerve and muscle interrelationship; studies in the pathologic physiology of poliomyelitis.

Authors:  S L RUSKIN; B C WILEY
Journal:  Int Rec Med Gen Pract Clin       Date:  1956-05

8.  Nucleotide levels in human cardiac muscle.

Authors:  W J BURDETTE
Journal:  Am Heart J       Date:  1957-11       Impact factor: 4.749

9.  Gradients of functional ability of importance in rehabilitation of patients with progressive muscular and neuromuscular diseases.

Authors:  C A SWINYARD; G G DEAVER; L GREENSPAN
Journal:  Arch Phys Med Rehabil       Date:  1957-09       Impact factor: 3.966

10.  The clinical significance of serum aldolase.

Authors:  J A SIBLEY; G A FLEISHER
Journal:  Proc Staff Meet Mayo Clin       Date:  1954-11-10
View more
  7 in total

1.  LAEVADOSIN FOR MUSCULAR DYSTROPHY.

Authors:  W H THOMSON
Journal:  Br Med J       Date:  1964-10-31

2.  LAEVADOSIN IN TREATMENT OF DUCHENNE TYPE OF MUSCULAR DYSTROPHY: PRELIMINARY RESULTS OF A DOUBLE-BLIND CONTROLLED TRIAL.

Authors:  J M PEARCE; S S GUBBAY; J HARDY; R J PENNINGTON; D J NEWELL; J N WALTON
Journal:  Br Med J       Date:  1964-10-10

3.  UNDESCENDED TESTES.

Authors:  R K CHANDRA
Journal:  Indian J Pediatr       Date:  1964-05       Impact factor: 1.967

Review 4.  MUSCULAR DYSTROPHY: SOME RECENT ADVANCES IN KNOWLEDGE.

Authors:  J N WALTON
Journal:  Br Med J       Date:  1964-05-23

5.  LAEVADOSIN IN MUSCULAR DYSTROPHY.

Authors:  J JACOBS
Journal:  Br Med J       Date:  1965-09-18

6.  LAEVADOSIN IN MUSCULAR DYSTROPHY.

Authors:  W H THOMSON
Journal:  Br Med J       Date:  1965-09-11

Review 7.  Metabogenic and Nutriceutical Approaches to Address Energy Dysregulation and Skeletal Muscle Wasting in Duchenne Muscular Dystrophy.

Authors:  Emma Rybalka; Cara A Timpani; Christos G Stathis; Alan Hayes; Matthew B Cooke
Journal:  Nutrients       Date:  2015-11-26       Impact factor: 5.717
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.